Navigation Links
New type of rejection blocker protects kidneys after transplant

In an international clinical trial, a new drug that selectively blocks immune responses has proved as effective in preventing acute kidney transplant rejection as cyclosporine, the standard anti-rejection treatment.

Patients who took the experimental drug, a co-stimulatory blocker called belatacept (LEA29Y), also had better kidney function and experienced less of the toxic side effects associated with standard anti-rejection drugs, including kidney damage, high blood pressure and high cholesterol.

In the August 25 issue of The New England Journal of Medicine, researchers report on the safety and efficacy of belatacept during a randomized phase II clinical study of 218 patients, conducted at 22 centers in the United States, Canada and seven European countries. Flavio Vincenti, MD, of the University of California, San Francisco, and Christian Larsen, MD, of Emory University in Atlanta, were co-principal authors of the study.

The results mark an important step toward proving the value of a new type of treatment based on blocking the immune system's reaction to a transplanted organ without hampering the body's ability to fight diseases and infections, according to Vincenti, clinical professor of medicine and surgery at UCSF and a kidney transplant specialist at UCSF Medical Center.

"This is the first clinical trial of a treatment for transplant recipients based on this new principle of inducing immune tolerance of the transplanted organ. If belatacept and similar drugs live up to their promise, they will usher in a new paradigm for organ transplantation," Vincenti said. Instead of sending patients home with a collection of medications that must be taken daily to prevent rejection by suppressing the immune system's hostile response to a transplanted organ, Vincenti said he expects his patients to receive an injected immune tolerance treatment a few times a year -- and perhaps to be able to stop taking anti-rejection drugs altogether.


'"/>

Source:University of California - San Francisco


Page: 1 2 3 4

Related biology news :

1. Simple sea sponge helps scientists understand tissue rejection
2. Researchers identify genes associated with lung transplant rejection
3. Carnegie Mellon develops non-invasive technique to detect transplant rejection at cellular level
4. Combination therapy with a monocloncal antibody and a vaccine leads to tumor rejection
5. Proteins may predict lung transplant rejection
6. Survival of heart patients on beta-blockers varies greatly with genetic variation
7. Bound for destruction: Ubiquitination protects against improper Notch signaling
8. Experiments provide proof of how traveling in groups protects insects
9. Experiments provide proof of how traveling in groups protects insects
10. Substance protects resilient staph bacteria
11. Molecule that usually protects infection-fighting cells may cause plaque deposits inside arteries
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New type rejection blocker protects kidneys after transplant

(Date:8/25/2015)... and BELLEVUE, Wash. , ... in advanced robotic systems, announced today it will unveil ... ground vehicle (UGV), at the National Tactical Officers Association ... The Guardian S is the first-ever commercially ... of years of research and in-field trials and is ...
(Date:8/24/2015)... 24, 2015  Based on its recent analysis of the ... 2015 African Biometrics Company of the Year Award. DERMALOG is ... success in Africa . It has particularly ... has implemented one of the largest biometric mass applications in ... the Central Bank of Nigeria with ...
(Date:8/20/2015)... CLARA, Calif. , Aug. 20, 2015 /PRNewswire/ ... company focused on improving the user experience and ... and vision technologies, today announced that its ... voice biometric authentication software to be FIDO ... tested TrulySecure for compliance with the FIDO UAF ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5
... Boston have developed a new nanobiotechnology that enables ... They describe the technology, which could lead to ... January issue of Nature Nanotechnology (published online January ... Mannix, PhD, of Childrens program in Vascular Biology, ...
... transcription -- the intricate transfer of information from a ... RNA -- isn,t stationed in special "transcription factories" within ... enzyme RNA polymerase II (Pol II) and other key ... gene, regardless of the gene,s position., The findings, published ...
... for Biomolecular Sciences (SBS) WHAT: Latest Findings and ... WHEN: April 6-10, 2008 WHERE: SBS ... BACKGROUND: More than 2,500 researchers and professionals ... expected to attend the 14th Annual Conference & Exhibition of ...
Cached Biology News:An 'attractive' man-machine interface 2An 'attractive' man-machine interface 3Research sheds light on the mechanics of gene transcription 2
(Date:8/27/2015)... ... 27, 2015 , ... Capital Edge Consulting , a nationwide consulting firm ... announce their ranking as one of the top 5000 companies listed on the ... the nation. , “It is truly an honor to be recognized as one of ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and six-month periods ended June 30, 2015. Biorem,s complete second quarter ... ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended ... 2014 , 2015 , 2014 Revenue ... , 4,433 Gross profit , 1,656 , ...
(Date:8/27/2015)... , Aug. 27, 2015 In ... by FedEx, UPS and The US Postal Service ... specimens classified as ,select agents, by the CDC, ... of handling these sensitive shipments. Marken ... transportation regulations, trained and certified personnel to ensure ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a ... development and manufacture of highly valued cardiac markers used in early detection of ... with protein chemistry has led to the development and commercialization of important cardiac ...
Breaking Biology Technology:Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2
... SilOnIS shared the 2007 Jean-Pierre Noblanc ... sustainable project in the EUREKA MEDEA+,microelectronics Cluster. ... and mobile multimedia applications that makes life ... value for network operators. SilOnIS combines strained ...
... for Women Seeking Relief of ... Menopausal Symptoms, ... Initiative (WHI) study published,today in the Journal of the American Medical ... therapy when it is,prescribed to symptomatic, newly menopausal women. Wyeth Pharmaceuticals, ...
... The Board of Directors of,Bristol-Myers Squibb Company (NYSE: ... per share on the $.10 par value Common,Stock of the ... to stockholders of record at the close of business on ... dividend of fifty cents ($0.50),per share on the $2.00 Convertible ...
Cached Biology Technology:MEDEA+ Noblanc award highlights improvements in microelectronics 2MEDEA+ Noblanc award highlights improvements in microelectronics 3WHI Findings Published in JAMA Do Not Affect Clinical Guidance for the Appropriate Use of Hormone Therapy 2WHI Findings Published in JAMA Do Not Affect Clinical Guidance for the Appropriate Use of Hormone Therapy 3WHI Findings Published in JAMA Do Not Affect Clinical Guidance for the Appropriate Use of Hormone Therapy 4